5-Amino-1MQ vs Efpeglenatide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: 5-amino-1-methylquinolinium, NNMT Inhibitor
First, a correction worth making loudly: 5-amino-1MQ is not a peptide. It is a small molecule (5-amino-1-methylquinolinium), and it gets lumped in with research peptides mostly because of the crowd that sells it. It blocks an enzyme called NNMT, and in obese mice it produced weight and fat loss without the animals eating less. No human trials have been published.
Also: Eppe, HM11260C
Efpeglenatide is a long-acting, once-weekly GLP-1 agonist from Hanmi Pharmaceutical, made by linking an exendin-4 analog to an antibody fragment so it lasts days instead of hours. Sanofi licensed it for diabetes in 2015 and handed it back in 2020 despite a positive heart outcomes trial. Hanmi relaunched it for obesity, and on 7 October 2026 South Korea approved it as Eppe, the country's first homegrown GLP-1 obesity drug. It is not approved by the FDA or EMA.
Key Comparison Insights
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Efpeglenatide has stronger research evidence (Human Trials) compared to 5-Amino-1MQ (Animal Studies).
Detailed Comparison
| Attribute | 5-Amino-1MQ | Efpeglenatide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | NNMT (nicotinamide N-methyltransferase) takes nicotinamide and tags it with a methyl group borrowed from SAM, the cell's main methyl donor, producing 1-methylnicotinamide. In fat tissue, high NNMT activity is thought to drain both NAD+ precursors and SAM, nudging cells toward storing fat. The hypothesis behind 5-amino-1MQ is straightforward: inhibit NNMT, and you preserve NAD+ and SAM inside adipocytes, which shifts them away from fat storage and toward burning energy. The published mouse work showed NNMT inhibition raising intracellular NAD+ and SAM, consistent with that idea. It is a plausible, well-reasoned mechanism, but in humans it remains a hypothesis, not a demonstrated effect. | Efpeglenatide activates the GLP-1 receptor, which raises insulin release after meals, lowers glucagon, slows stomach emptying and reduces appetite. The active part is an exendin-4 analog (the same parent peptide as exenatide and lixisenatide) attached through a small linker to a human IgG4 Fc fragment, using Hanmi's LAPSCOVERY platform. The Fc piece makes the molecule big enough to dodge kidney clearance and lets it recycle in the body, which stretches its half-life to weekly dosing. Hanmi argues its lower brain penetration explains the milder GI profile; that is a company argument rather than an independently proven fact. |
| Common Dosing | 50-75 mg daily Once daily, morning | 10 mg once weekly maintenance (Korean label) Once weekly |
| Administration | Subcutaneous injection or oral | Subcutaneous auto-injector once weekly |
| Typical Duration | 4-6 weeks (cycling recommended) | Long-term (chronic weight management); 40-64 weeks in the Korean phase 3 |
| Best Time to Take | Morning, fasted | Same day each week |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The headline study (Neelakantan et al.) tested small-molecule NNMT inhibitors in diet-induced obese mice. Treated animals lost weight (roughly 5% from baseline over about 11 days in that work) and shed white adipose mass, with reduced circulating cholesterol and no change in food intake, which points to a metabolic effect rather than appetite suppression. That is genuinely interesting preclinical data. But here is the honest part: the entire evidence base is animal and cell studies. There are no published human clinical trials demonstrating that 5-amino-1MQ causes fat loss, raises energy expenditure, or is safe over time in people. Claims of specific human fat-loss percentages from vendors are not backed by trial data. Treat it as an early-stage research compound, not a proven product. | The strongest data come from Sanofi's AMPLITUDE-O trial (NEJM 2021), which enrolled people with type 2 diabetes and cardiovascular or kidney disease. Efpeglenatide 4 or 6 mg weekly cut major cardiovascular events by 27% versus placebo (7.0% vs 9.2%, hazard ratio 0.73) over a median of 1.8 years, and also reduced kidney outcomes. Sanofi still returned the rights in 2020 for business reasons. Hanmi then ran a Korean phase 3 obesity trial in 448 adults without diabetes (average BMI 32): at 40 weeks, weight loss was 9.02% versus 0.89% on placebo, and 75.1% lost at least 5%. That is less weight loss than semaglutide or tirzepatide in their pivotal trials, though trial designs differ, and GI side effects were somewhat lower (diarrhea 17.6%, nausea 16.6%, vomiting 11.6%). Korea's MFDS approved it for chronic weight management on 7 October 2026, with launch planned for late October. Bottom line: a solid, proven drug class member with real outcome data, but modest weight loss and no Western approval. |
Frequently Asked Questions: 5-Amino-1MQ vs Efpeglenatide
What is the difference between 5-Amino-1MQ and Efpeglenatide?
5-Amino-1MQ is a weight loss peptide that first, a correction worth making loudly: 5-amino-1mq is not a peptide. it is a small molecule (5-amino-1-methylquinolinium), and it gets lumped in with research peptides mostly because of the crowd that sells it. it blocks an enzyme called nnmt, and in obese mice it produced weight and fat loss without the animals eating less. no human trials have been published. Efpeglenatide is a weight loss peptide that efpeglenatide is a long-acting, once-weekly glp-1 agonist from hanmi pharmaceutical, made by linking an exendin-4 analog to an antibody fragment so it lasts days instead of hours. sanofi licensed it for diabetes in 2015 and handed it back in 2020 despite a positive heart outcomes trial. hanmi relaunched it for obesity, and on 7 october 2026 south korea approved it as eppe, the country's first homegrown glp-1 obesity drug. it is not approved by the fda or ema. The main differences lie in their mechanisms of action and clinical applications.
Which is better, 5-Amino-1MQ or Efpeglenatide?
Neither is universally "better" - the choice depends on your specific goals. 5-Amino-1MQ is typically used for weight loss purposes, while Efpeglenatide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can 5-Amino-1MQ and Efpeglenatide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using 5-Amino-1MQ and Efpeglenatide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.